Search results
Results from the WOW.Com Content Network
BioNTech was founded in 2008 based on research by Uğur Şahin, Özlem Türeci, [8] and Christoph Huber, [9] with a seed investment of €180 million [10] from MIG Capital, a Munich-based venture capital firm, the family office of Andreas and Thomas Strüngmann, and the present chairman of the supervisory board, Helmut Jeggle.
The Pfizer–BioNTech COVID-19 vaccine, sold under the brand name Comirnaty, [2] [33] is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. For its development, BioNTech collaborated with the American company Pfizer to carry out clinical trials, logistics, and manufacturing.
With the acquisition, BioNTech will obtain full global rights to the late-stage clinical asset BNT327/PM8002, an investigational bispecific antibody targeting PD-L1 and VEGF-A. Truist initiated ...
BioNTech said partner Pfizer will reimburse it for up to $170 million of the royalties payable to Penn and $364.5 million of the royalties paid to the National Institutes of Health (NIH)for 2020 ...
The couple – interviewed on BBC’s Sunday with Laura Kuenssberg programme – co-founded BioNTech in Mainz, Germany, in 2008, and worked to pioneer cancer immunotherapies tailored to individual ...
Together with Özlem Türeci and Christoph Huber, Şahin founded the biotechnology company BioNTech, based in Mainz, Germany, in 2008 and serves as its CEO. [45] [46] BioNTech is focused on developing and manufacturing active immunotherapies for a patient-specific approach to the treatment of cancer and other serious diseases. [47]
(Reuters) - Germany's BioNTech SE said in a regulatory filing on Monday the U.S. Food and Drug Administration has placed a partial clinical hold on an early-stage study of its experimental cancer ...
Özlem Türeci (Turkish pronunciation: [ˈœzlem ˈtyredʒi]; born 6 March 1967) is a German physician, scientist and entrepreneur. In 2008, she co-founded the biotechnology company BioNTech, which in 2020 developed the first messenger RNA-based vaccine approved for use against COVID-19. [2]